Cardio-cerebrovascular protective effects of Valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study)

American Journal of Cardiology

Volumn 109, Issue 9, 2012, Pages 1308-1314

  Shiraishi, Jun ^a   Sawada, Takahisa ^b   Koide, Masahiro ^b   Yamada, Hiroyuki ^b   Matsubara, Hiroaki ^b  

^a KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VALSARTAN;

ACUTE HEART INFARCTION; ADD ON THERAPY; AGED; ANGINA PECTORIS; AORTA DISSECTING ANEURYSM; ARTICLE; BLOOD PRESSURE FLUCTUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; MALE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 84859801322     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.12.025     Document Type: Article

References (12)

1. Sawada T, Yamada H, Dahlöf B, Matsubara H; Kyoto Heart Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart study. Eur Heart J 2009;30:2461-2469.
2. Sawada T, Takahashi T, Yamada H, Dahlöf B, Matsubara H; Kyoto Heart Study Group. Rationale and design of the Kyoto Heart study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens 2009;23:188-195.
3. Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. Circ J 2009;73:1080-1085.
4. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, Saruta T, Nakao K. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Circ J 2011;75:2411-2416.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
6. Fox KM; European Trail on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet 2003;362: 782-788.
7. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588. (Pubitemid 44209181)
8. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010;105(suppl):21A-29A.
9. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010;105(suppl):30A-35A.
10. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009;30:1203-1212.
11. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. (Pubitemid 351522739)
12. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;35:2058-2068.